Healthcare at Home is a pharmaceutical supplier established in 1992 by founder and former chairman Charles Walsh based in Burton on Trent.
The company supplies a wide range of pharmaceuticals and home healthcare with around 1,000 employees caring for more than 150,000 patients a year.
In Spring 2015, Healthcare at Home reverted to using in house logistics rather than working with a third party for all deliveries.
In Autumn 2015, the company went through a full corporate rebranding, including new logos, literature, strap line and website in an attempt to re-establish the company's status in the market.
Previous Issues
In 2013 Healthcare at Home took over almost 3,000 patients from another drug delivery company, Medco Health Solutions which pulled out of the UK market. Subsequently the company struggled to maintain services. In March 2014 Healthcare at Home said that it was no longer accepting new ‘high risk’ patients such as those suffering from haemophilia or respiratory diseases like cystic fibrosis because it could not guarantee getting their drugs to them on time or in full. The company blamed IT issues and a ‘system failure’ relating to the firm’s outsourcing of its logistics and warehousing departments. Dave Roberts, chief executive of the National Clinical Homecare Association, says there are questions about whether the rapid growth and low profit margins in the sector have contributed to the situation. ‘There’s been 20% growth in this sector year on year for several years now in terms of numbers of patients – that’s a very rapid expansion. But profits in this sector are just 2-4%. That is a poor return given the extent of capital investment needed and the governance and logistics issues. As NHS budgets have fallen, all the slack has been cut out of contracts,’ Roberts added.
In its most recent published accounts Healthcare at Home, which is majority-owned by private equity firm Vitruvian Partners, reported a turnover of £1bn, with pretax profits of just £15m.
The chief executive Mike Gordon stepped down in June 2014 after the revelation that seven per cent of the firm’s 150,000 patients had not received their medication on time or in full during the last six months.